Versartis to Host Conference Call to Review Two-Year Top-Line Data From Ongoing Extension Study of Somavaratan

Conference Call and Webcast Featuring Guest Speaker Dr. Bradley Miller Scheduled at 7:30 a.m. ET on February 2, 2016

Management to Participate in the Canaccord Genuity 2016 Rare Disease, BioPharma 1x1 Day

MENLO PARK, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that it will hold a conference call and webcast on February 2, 2016 at 7:30 a.m. ET (4:30 a.m. PT) to review two-year, top-line data from the ongoing somavaratan Extension Study in children with GHD.

The Extension Study is a long-term safety study that was initiated in March 2014 as patients completed the Phase 1b/2a clinical trial evaluating somavaratan therapy in treatment-naive, pre-pubertal GHD children. During the call, Versartis management will provide a top-line overview of two-year safety, efficacy and adherence data. Bradley S. Miller, M.D., Ph.D., Associate Professor in the Department of Pediatric Endocrinology at the University of Minnesota Masonic Children's Hospital and a study investigator, will reflect on the data and take questions from participants. A press release summarizing the data will be issued on February 2, 2016 prior to the call. Detailed results of the two-year data are being preserved for submission to a future scientific conference.

Following the call, Versartis management will participate in the Canaccord Genuity 2016 Rare Disease, BioPharma 1x1 Day on February 2, 2016 at the Omni Berkshire Place Hotel in New York City.

Conference Call and Webcast

The conference call is scheduled for Tuesday, February 2, 2016 at 7:30 a.m. ET. The dial-in numbers are 877-407-0789 for domestic callers and 201-689-8562 for international callers. A live webcast of the conference call including a slide presentation will be available online from the investor relations page of the Company's corporate website at

After the live webcast, the call will remain available on the Versartis website,, for 90 days. In addition, a telephonic replay of the call will be available until February 16, 2016. The replay dial-in numbers are 877-870-5176 for domestic callers and 858-384-5517 for international callers. Please use the replay conference ID number 13629447.

About Versartis, Inc.

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of growth hormone deficiency (GHD) in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. Versartis’ clinical trials can be found at For more information on Versartis, visit

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, plans and timing of our clinical trials and the potential for eventual regulatory approval of somavaratan. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2014, and in our Quarterly Report on Form 10-Q for the three months ended September 30, 2015, which are on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contacts: Corporate & Investors: Joshua Brumm Chief Financial Officer (650) 963-8582 Corporate Communications: Christine Labaree Evergreen Communications (650) 600-1697 Investors: Nick Laudico/David Burke The Ruth Group (646) 536-7030/7009